MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 Update

MacroGenics Inc MGNX reported Tuesday after the close with forecast-beating first-quarter results and said it has adequate cash to operate into 2022. The company also issued an update on its clinical pipeline.

The MacroGenics Analyst

SVB Leerink analyst Jonathan Chang reiterated an Outperform rating on MacroGenics and nudged down the price target from $16 to $15.

The MacroGenics Thesis

The several pipeline updates MacroGenics issued on its earnings call are positive for the company and a testament to the considerable opportunity provided by its broad portfolio of antibody-based therapies, Chang said in a Wednesday note. (See his track record here.)

The analyst said he's awaiting detailed data from the programs and more clarity on the path forward, adding that several of MacroGenics' opportunities represent upside to his current estimates.

Multiple data presentations at Virtual American Society of Clinical Oncology 2020 conference will be the next catalyst, Chang said. The presentation includes an oral presentation of MGD013 and posters for the antibody conjugate MGC018 and margetuximab.

"Overall, we remain OP at current levels and see multiple sources of upside within MGNX's broad and deep pipeline of proprietary and partnered programs," the analyst said. 

MCGNX Price Action

At last check, MacroGenics shares were surging by 218.45% to $24.20.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Posted In: Jonathan ChangSVB LeerinkAnalyst ColorBiotechEarningsNewsPrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.